Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity

Cancer immunotherapy targeting the TIGIT/PVR pathway is currently facing challenges. KIR2DL5, a member of the human killer cell, immunoglobulin-like receptor (KIR) family, has recently been identified as another binding partner for PVR. The biology and therapeutic potential of the KIR2DL5/PVR pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Xiaoxin, Peng, Mou, Xing, Peng, Wei, Yao, Galbo, Phillip M., Corrigan, Devin, Wang, Hao, Su, Yingzhen, Dong, Xiaoshen, Sun, Qizhe, Li, Yixian, Zhang, Xiaoyu, Edelmann, Winfried, Zheng, Deyou, Zang, Xingxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663162/
https://www.ncbi.nlm.nih.gov/pubmed/36377656
http://dx.doi.org/10.1172/JCI163620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663162/
https://www.ncbi.nlm.nih.gov/pubmed/36377656
http://dx.doi.org/10.1172/JCI163620

Ejemplares similares